<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110939</url>
  </required_header>
  <id_info>
    <org_study_id>HenanCH2016ct082</org_study_id>
    <nct_id>NCT03110939</nct_id>
  </id_info>
  <brief_title>Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer</brief_title>
  <official_title>A Phase III, Single Center Randomized Controlled Trial of Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to explore whether intrathoracic hyperthermic
      perfusion after radical surgery could reduce local recurrence rate(13%) for advanced lung
      cancer / esophageal cancer. The safety of intrathoracic hyperthermic perfusion right after
      surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2017</start_date>
  <completion_date type="Anticipated">April 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local recurrent rate</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>recurrent within thoracic cavity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total complication rate</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>The total complications mean anastomotic fistula, hydrothorax, pneumonia, pleural hemorrhage and cardiac together.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Clavien-Dindo classification</measure>
    <time_frame>6 months after surgery</time_frame>
    <description>the classification surgical complications after surgery/intrathoracic hyperthermic perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate during operation/intrathoracic hyperthermic perfusion</measure>
    <time_frame>during operation/intrathoracic hyperthermic perfusion</time_frame>
    <description>mortality rate during operation/intrathoracic hyperthermic perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs during treatment</measure>
    <time_frame>during operation/intrathoracic hyperthermic perfusion</time_frame>
    <description>The heart rate, blood pressure and body temperature will be recorded every 10 mins during intrathoracic hyperthermic perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate after treatment</measure>
    <time_frame>2 months after surgery/intrathoracic hyperthermic perfusion</time_frame>
    <description>mortality rate after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Hyperthermic Perfusion</condition>
  <arm_group>
    <arm_group_label>hyperthermic perfusion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after standard surgery of advanced lung cancer/esophageal cancer)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard surgery of advanced lung cancer/esophageal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hyperthermic perfusion</intervention_name>
    <description>hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)</description>
    <arm_group_label>hyperthermic perfusion group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must not have received any prior anticancer therapy of cancer.

          2. expected R0 resection.

          3. Histologic diagnosis of squamous cell thoracic esophageal carcinoma of T3-4, any N and
             any T, N1. (8th Union for International Cancer Control, Union for International Cancer
             Control(UICC)-TNM). Histologic diagnosis of non small cell lung cancer, T2-T3, any N.
             (8th Union for International Cancer Control, UICC-TNM)

          4. Age ranges from 18 to 80 years.

          5. Without operative contraindication.

          6. Eastern Cooperative Oncology Group (ECOG) 0～2.

          7. Signed informed consent document on file.

        Exclusion Criteria:

          1. Multiple primary cancer.

          2. The subject cannot understand and sign the informed consent form(ICF).

          3. Patients with concomitant hemorrhagic disease.

          4. Any un expected reason for patients can't get operation.

          5. Pregnant or breast feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university</name>
      <address>
        <city>ZhengZhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin Li, M.D.&amp; Ph.D.</last_name>
      <phone>8613903838752</phone>
      <email>liyin825@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Yan Zheng, M.D.&amp; Ph.D.</last_name>
      <phone>8615713660065</phone>
      <email>sunnyzheng1@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yin Li, M.D.&amp; Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Yin Li</investigator_full_name>
    <investigator_title>vice president of Henan Cancer Hospitan and director of thoracic surgery department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

